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ABSTRACT
Women with endometriosis can suffer from decreased
fecundity or complete infertility via abnormal oocyte function
or impaired placental-uterine interactions required for normal
pregnancy establishment and maintenance. Although AT-rich
interactive domain 1A (SWI-like) (ARID1A) is a putative tumor
suppressor in human endometrial cancers and endometriosis-
associated ovarian cancers, little is known about its role in
normal uterine function. To study the potential function of
ARID1A in the female reproductive tract, we generated mice
with a conditional knockout of Arid1a using anti-Mu¨llerian
hormone receptor 2-Cre. Female Arid1a conditional knockout
mice exhibited a progressive decrease in number of pups per
litter, with a precipitous decline after the second litter. We
observed no tumors in virgin mice, although one knockout
mouse developed a uterine tumor after pregnancy. Unstimulated
virgin female knockout mice showed normal oviductal, ovarian,
and uterine histology. Uteri of Arid1a knockout mice showed a
normal decidualization response and appropriate responses to
estradiol and progesterone stimulation. In vitro studies using
primary cultures of human endometrial stromal fibroblasts
revealed that small interfering RNA knockdown of ARID1A did
not affect decidualization in vitro. Timed pregnancy studies
revealed the significant resorption of embryos at Embryonic Day
16.5 in knockout mice in the third pregnancy. In addition to
evidence of implantation site hemorrhage, pregnant Arid1a
knockout mice showed abnormal placental morphology. These
results suggest that Arid1a supports successful pregnancy
through its role in placental function.
ARID1A, female reproductive tract, fertility, genetically
engineered mouse models, placenta, tumor suppressor, uterus
INTRODUCTION
The AT-rich interactive domain 1A (SWI-like) (Arid1a)
gene encodes a large nuclear protein that is a key subunit of the
multiprotein SWI/SNF chromatin-remodeling complex that is
present in all eukaryotes. The SWI/SNF complex regulates
gene expression for a variety of cellular processes, including
differentiation, proliferation, DNA repair, and tumor suppres-
sion. The complex uses ATP as energy to mobilize
nucleosomes, thereby modulating the accessibility of promot-
ers to transcriptional activation or repression [1, 2].
Loss of ARID1A has been discovered in many human
cancers, including renal cell carcinoma, gastric carcinoma,
bladder tumors, pancreatic cancer, colon cancer, breast cancer,
endometriosis-associated ovarian carcinomas, and uterine
endometrioid carcinomas [3–20]. Considering gynecological
cancer types, ARID1A mutation is a driver mutation for
endometrial cancer, giving an advantage to epithelial cell
growth in vitro [19]. Evidence from ovarian cancer cell lines
supports the idea that ARID1A functions as a tumor suppressor
by binding to tumor protein p53 (TP53) and regulating cyclin-
dependent kinase inhibitor 1A (CDKN1A) [20].
Although ARID1A-inactivating mutations occur in a wide
variety of tumors of the female reproductive tract in humans,
inactivation of ARID1A alone is insufficient for tumor
initiation in the female reproductive tract of mice [21, 22].
Studies using adenovirus-driven Cre to delete Arid1a in the
ovarian surface epithelium showed that deletion of Arid1a
alone is not sufficient for ovarian cancer formation. Rather,
female reproductive tract tumor formation required additional
mutation in phosphatase and tensin homolog (Pten) or
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic sub-
unit alpha (Pik3ca) [22, 23]. Studies using progesterone
receptor (Pgr)-driven Cre to delete Arid1a in the uterus
showed that deletion of Arid1a alone is not sufficient for
endometrial cancer formation [21]. Although these studies
suggest the potential cooperation between mutation of Arid1a
and other tumor suppressors in tumorigenesis, little is known
about the role of ARID1A in the normal female reproductive
tract.
ARID1A is essential for mammalian development because
deletion of Arid1a in traditional knockout mice causes
embryonic lethality resulting from defects in mesoderm
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development and embryonic stem cell self-renewal, differen-
tiation, and cell lineage decisions [24]. To overcome this early
defect and study the global roles of ARID1A in mammals,
others have developed Arid1a floxed alleles [24] for the
conditional ablation of Arid1a, which has shed light on the role
of Arid1a in regulating key genes in cardiac development [25].
Recently, we showed that deletion of Arid1a from the Pgr-
positive cells of the uterus resulted in complete sterility with
defective embryo implantation and uterine decidualization. The
underlying mechanism of this sterility phenotype was from the
effects of ARID1A and PGR on expression of Kruppel-like
factor 15 (Klf15) and on uterine epithelial cell proliferation
[21]. To study the broader role of Arid1a in the female
reproductive tract, we used the anti-Mu¨llerian hormone
receptor 2 (Amhr2)-Cre mouse model [26], which has Cre
recombinase inserted into the Amhr2 gene. Therefore, Cre is
expressed in cells that express Amhr2, which include
mesenchymal cells of the uterus such as uterine stromal and
myometrial cells, oviductal cells, and somatic cells of the ovary
such as surface epithelial and granulosa cells [26–30].
Expression of Amhr2 is detectable as early as the 8-cell stage
[31], and its expression in the gonad is present beginning at
Embryonic Day 12.5 [27]. Amhr2-Cre mice have been
successfully used to study the roles of many genes in female
reproduction and cancer, including vascular endothelial growth
factor a (Vegfa) [32], miR-34c [33], signal transducer and
activator of transcription 3 (Stat3) [34], transforming growth
factor beta receptor 1 (Tgfbr1) [35], transformation protein
related protein 53 (Trp53) [36–38], Pten [28, 36, 37, 39–42],
Kirsten rat sarcoma viral oncogene homolog (Kras) [28, 36, 37,
43], beta catenin 1 (Ctnnb1) [29, 39, 44–47], tuberous sclerosis
1 (Tsc1) [48, 49], smoothened, frizzled class receptor (Smo)
[50–53], adenomatous polyposis coli (Apc) [54], wingless-type
MMTV integration site family, member 4 (Wnt4) [55], breast
cancer 1, early onset (Brac1) [38], Dicer1 [42, 56–58], nuclear
receptor subfamily 2, group F, member 2 (Nr2f2) [59], splicing
factor 1 (Sf1) [60], activins [61], follistatin (Fst) [62], and
Smads [63, 64]. Here, using Amhr2-Cre mice, we show that
deletion of Arid1a leads to a progressive loss of fertility via
placental disruption.
MATERIALS AND METHODS
Generation and Genotyping of Arid1a Conditional
Knockout Mice
Arid1a conditional allele (Arid1aflox/flox) mice have been described
previously [24] and were maintained in a C57BL/6J; 129S5/Brd mixed
hybrid background. Arid1aflox/flox mice were bred to Amhr2cre/þ mice [26] to
generate Arid1aflox/þ;Amhr2cre/þ mice. Arid1aflox/þ;Amhr2cre/þ male mice
were crossed to Arid1aflox/flox female mice to generate final breeder pairs of
Arid1aflox/flox;Amhr2cre/þ male mice and Arid1aflox/flox female mice. These
final breeders were used to generate the experimental female mice:
Arid1aflox/flox;Amhr2cre/þ mice (termed Arid1a conditional knockout [cKO]
mice) and Arid1aflox/flox mice (termed control mice) (Supplemental Fig.
S1A; Supplemental Data are available online at www.biolreprod.org).
Arid1aflox/-;Amhr2cre/þ mice were not generated because previous studies
show that Arid1a heterozygosity (Arid1aþ/) leads to embryonic lethality in
mice, similar to homozygous deletion [24]. All mice were maintained in
accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals under an approved protocol. The Baylor College
of Medicine Genetically Engineered Mouse Core performed rederivation
and initial breeding. Mice were genotyped at 12–14 days of postnatal life
from tail biopsies by PCR analyses using specific primers [22, 65]
(Supplemental Table S1 and Supplemental Fig. S1B). For the Arid1a floxed
allele, the following conditions were used with Arid1a forward and reverse
primers: 2 min at 508C, 10 min at 958C, followed by 40 cycles of 15 sec at
958C (denaturation), 45 sec at 598C (annealing), and 45 sec at 728C
(extension). For the Cre allele, the following conditions were used with
Amhr2-Cre forward and reverse primers: 2 min at 508C, 10 min at 958C,
followed by 40 cycles of 15 sec at 958C (denaturation), 45 sec at 608C
(annealing), and 45 sec at 728C (extension).
Fertility Analysis and Studies Involving Parous Uteri
To evaluate reproductive performance, 6-wk-old female control and Arid1a
cKO mice were bred to wild-type C57BL/6J;129S5Brd hybrid male mice of
proven fertility. The numbers of litters and pups were recorded over a 6-mo
period. After the 6-mo fertility studies were completed, female mice were rested
for 2 mo. Mice were then euthanized, and the parous uteri were fixed for
histology.
Tissue Collection, Histological Analysis, and Timed
Pregnancy
At times listed in experimental design below, mice were euthanized;
reproductive organs were excised and fixed for histology or snap frozen for
RNA or protein isolation. Uteri, implantation sites, and placentas were fixed in
4% paraformaldehyde (Sigma), and ovaries were fixed in 10% neutral buffered
formalin (EMD Millipore). The Baylor College of Medicine Human Tissue
Acquisition and Pathology Core performed tissue processing and paraffin
embedding. Sections were cut at 5 lm and stained with hematoxylin (VWR)
and eosin (VWR) or periodic acid-Schiff (Sigma) using standard techniques.
Tissue and serum samples from timed pregnancies were obtained by mating
Arid1a cKO and control female mice with intact wild-type C57BL/6;129S5/
Brd hybrid male mice. The morning that the vaginal plug was observed was
designated as 0.5 days postcoitus (dpc). Mice were euthanized on Day 4.5, 8.5,
9.5, or 16.5 of pregnancy, and the number of implantation sites was counted.
Steroid Hormone Treatment and Artificial Induction of
Decidualization
Beginning at 6 wk of age, Arid1a cKO and control female mice underwent
bilateral ovariectomy followed by rest for 2 wk. For steroid hormone
responsive studies, mice were treated with either 1 mg progesterone (P4) for
6 h [66, 67] or 100 ng 17b-estradiol (E2) for three consecutive days [68].
Sesame oil was used as a vehicle control (all reagents from Sigma).
The artificial induction of uterine decidualization has been previously
described [69]. Briefly, 2 wk after ovariectomy, Arid1a cKO and control female
mice were primed with 100 ng E2 per day for 3 days, followed by 2 days of rest
and then 3 daily injections of 1 mg P4 and 6.7 ng E2. Six hours after the last
injection, the left uterine horn was stimulated by a scratch with a burred needle.
Daily injections of 1 mg P4 and 6.7 ng E2 were continued for 5 days. Mice
were euthanized on Day 5. The uteri were dissected, weighed, and fixed in 4%
paraformaldehyde.
Superovulation
Superovulation experiments were carried out as previously described [70].
At 21 days of age, Arid1a cKO and control female mice were injected
intraperitoneally with 5 IU equine chorionic gonadotropin (Calbiochem) for 46
h, followed by intraperitoneal injection with 5 IU human chorionic
gonadotropin (Novarel; Ferring Pharmaceuticals). Mice were then bred to
wild-type male mice with proven fertility. Mice were dissected at 4.5 dpc.
Serum Analysis
Adult Arid1a cKO and control female mice were anesthetized by isoflurane
inhalation (Abbott Laboratories), and blood was collected in microtainer tubes
(Becton Dickinson) by closed cardiac puncture. Serum was separated by
centrifugation and stored at208C until use. The University of Virginia Ligand
Assay and Analysis Core performed measurements of follicle stimulating
hormone (FSH), luteinizing hormone (LH), anti-Mu¨llerian hormone (AMH),
E2, and P4 levels.
Immunohistochemical Staining
Three sections from each of three independent control and Arid1a cKO
uteri or ovary were analyzed in parallel. Paraffin-embedded tissues were cut at
5 lm, mounted on silane-coated slides, deparaffinized, rehydrated in graded
alcohol series, and boiled in citrate buffer, pH 6.0 (Abcam) prior to blocking
with 10% normal goat serum and incubating in primary antibody diluted in
10% normal goat serum (Vector Laboratories) in phosphate-buffered saline
(PBS), pH 7.5 (Life Technologies, Inc.) overnight at 48C. Primary antibodies
and conditions are listed in Supplemental Table S2. Sections were washed with
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PBS and incubated with the appropriate species-specific horseradish peroxi-
dase-conjugated secondary antibody (2 lg/ml; Vector Laboratories) for 1 h at
room temperature. Immunoreactivity was detected using the Vectastain Elite
DAB kit (Vector Laboratories). Sections were then briefly counterstained with
hematoxylin, dehydrated, and mounted. Slides were analyzed by light
microscopy.
RNA Isolation and Real-Time Quantitative PCR Analysis
Total RNA was extracted using the mirVana microRNA isolation kit (Life
Technologies, Inc.). After nucleic acid quantification on a NanoDrop ND-1000
(Thermo Scientific), RNA was treated with Turbo DNAse (Life Technologies,
Inc.) according to the manufacturer’s protocol. DNAse-treated RNA (1000 ng)
was reverse transcribed in a 50 ll reaction using 250 U Superscript III reverse
transcriptase (Life Technologies, Inc.) with random primers (Life Technologies,
Inc.). Samples were diluted to 100 ll, and 2 ll was used for each quantitative
PCR (qPCR) reaction. Real-time qPCR was performed on the ABI
StepOnePlus using either predesigned TaqMan Gene Expression Assays (Life
Technologies, Inc.) or custom primers designed using Primer Express software
(Life Technologies, Inc.) for SYBR green (Supplemental Table S1). Levels of
mouse ribosomal protein L13a (Rpl13a) or 18s were used as endogenous
controls for mouse uterus samples as expression of Rpl13a and 18s were shown
not to change in response to steroid hormone stimulation [66, 71]. Levels of
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) were used for placenta as
previous studies have shown this is a reasonable endogenous control for mouse
placenta [72, 73]. Levels of human ribosomal protein L19 (RPL19) were used
as endogenous controls for human samples [66, 74–76]. TaqMan PCR was
performed using TaqMan universal PCR master mix (Life Technologies, Inc.),
and PCR with custom primers was performed using SYBR Green PCR master
mix (Life Technologies, Inc.) in a 10-ll reaction. The reaction conditions were
as follows: 2 min at 508C, 10 min at 958C, followed by 40 cycles of 15 sec at
958C (denaturation) and 1 min at 608C (annealing/extension). Each sample was
analyzed in duplicate or triplicate, and a nontemplate control (nuclease-free
water) was included on each plate for each primer-probe set. All custom
primers had an efficiency of 85%–110%. All SYBR green runs had dissociation
curves to predict potential primer-dimers. The relative quantity of transcript
was calculated using the 2DDCt method [77].
Institutional Review Board Approval, Collection of Human
Tissues, Creation of Primary Cultures, and Transfection of
Cells
All human tissues were collected under Baylor College of Medicine
Institutional Review Board approval with written informed consent, and
cultures were created as described previously [76]. Cells were transfected and
underwent in vitro decidualization as described previously [78]. Briefly, 2 days
before induction of in vitro decidualization, cells in 6-well plates were treated
with Dulbecco-modified Eagle medium/F12 with 2% charcoal-stripped fetal
bovine serum (Life Technologies, Inc.) containing 5 ll RNAiMax (Life
Technologies, Inc.) with 100 nM of either nontargeting small interfering RNA
(siNT) (ON-TARGETplus Non-targeting Control Pool, Thermo Scientific) or
small interfering RNA targeting ARID1A (siARID1A) (ON-TARGETplus
Human ARID1A small interfering RNA, Thermo Scientific) dissolved in Opti-
MEM (Invitrogen). On the day of decidualization induction, which was
designated as Day 0, an aliquot of cells for each treatment (siNT or siARID1A)
was collected, and the remaining cells were treated with decidual medium
containing 108 M E2, 106 M medroxyprogesterone acetate, and 50 lM 8-
bromocyclic AMP in Opti-MEM with 2% charcoal-stripped fetal bovine serum
and 1% antibiotic-antimycotic (Invitrogen) as described previously [76]. The
medium was changed using freshly prepared decidual medium on Days 2 and
4. On Day 6, cells were washed with PBS, scraped from plates, and harvested
in lysis buffer for RNA isolation as described above.
Statistical Analysis
Student t-test or two-way ANOVA with post hoc tests were performed
using GraphPad Prism software version 6.0c. For the timed pregnancy study,
chi-square analysis was performed. Data are presented as mean 6 standard
error of the mean, and P , 0.05 was considered statistically significant.
RESULTS
Arid1a cKO Mice Did Not Develop Ovarian Cancer
To generate female mice lacking expression of Arid1a in the
reproductive tract, Arid1aflox/flox mice [24] and Amhr2cre/þ mice
[26] that express Cre recombinase under the control of the
Amhr2 promoter were obtained. Supplemental Figure S1A
shows the detailed breeding strategy to generate Arid1aflox/flox;
Amhr2cre/þ mice (termed Arid1a cKO mice) and Arid1aflox/flox
mice (termed control mice). Previous studies show that similar
strategies are successful in disrupting ARID1A function [21,
24, 25].
We found that female Arid1a cKO and control mice were
born healthy. To confirm tissue-specific recombination and
ablation of Arid1a, we performed qPCR and immunohisto-
chemical staining on tissues from virgin 12-wk-old female
mice. Quantitative PCR revealed a 1.58-fold decrease (n ¼ 8,
Student t-test, P ,0.05) in Arid1a in whole uteri of adult
Arid1a cKO mice compared with control mice (Fig. 1A). This
sizeable but incomplete ablation of Arid1a in the uterus may be
due to the lack of Arid1a deletion in the uterine epithelium.
Next, we used immunohistochemistry to examine the cell type-
specific expression of ARID1A. In uteri from virgin control
female mice, ARID1A was expressed in the nuclei of uterine
luminal and glandular epithelial cells, uterine stromal cells, and
myometrial cells (Fig. 1, B and C). In uteri from virgin Arid1a
cKO female mice, there was a lack of ARID1A staining in the
uterine stroma but observable staining in uterine luminal and
glandular epithelial cells (Fig. 1, D and E). This cell type-
specific depletion of ARID1A in the uterus is consistent with
previous work showing AMHR2 expression in uterine stromal
cells [30]. Thus, as expected, ablation of Arid1a in the uterus of
cKO mice was cell type specific.
Amhr2-Cre should lead to recombination in somatic cells of
the ovary, including granulosa cells and ovarian surface
epithelial cells [26, 28]. In virgin 12-wk-old female control
mice, ARID1A was detected in ovarian theca cells, in somatic
cells of ovarian follicles at all stages of follicular development,
and in ovarian surface epithelial cells (Supplemental Fig. S2, A
and B). In unstimulated virgin female Arid1a cKO mice, there
was decreased ARID1A staining in granulosa cells and ovarian
surface epithelial cells (Supplemental Fig. S2, C and D).
Previous work had shown that deletion of Pten and Dicer using
Amhr2-Cre lead to high-grade serous ovarian cancers that arose
in the oviduct [42]. ARID1A was detected in nuclei of the
columnar epithelium of the oviduct in both virgin control
(Supplemental Fig. S2, E and F) and Arid1a cKO mice
(Supplemental Fig. S2, G and H).
Because loss of ARID1A in epithelial cells is a common
feature of human endometriosis-associated ovarian cancers [9,
11], we performed long-term survival studies with virgin
female control and Arid1a cKO mice (n ¼ 20 per genotype).
We observed no differences (P¼ 0.575) between genotypes in
body weight over time (Supplemental Fig. S3). No control or
Arid1a cKO mice were euthanized due to disease. Furthermore,
at 1 yr of age, both virgin control and virgin Arid1a cKO mice
had normal reproductive tract histology (data not shown).
These results indicate that virgin female Arid1a cKO mice did
not develop ovarian cancer.
Arid1a cKO Mice Exhibited a Progressive Decline in
Fertility
To evaluate fertility, female control and Arid1a cKO mice
(n ¼ 9 per genotype) were housed with wild-type males for 6
mo. Arid1a cKO mice were less fertile than control mice, with
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significantly fewer pups per litter (Student t-test, P, 0.05; Fig.
2A) and significantly fewer litters per month (cKO: 0.7 6 0.3;
control: 1.1 6 0.1; Student t-test, P , 0.05). Litter size was
significantly smaller in Arid1a cKO mice (4.0 6 1.9 pups per
litter) compared with control female mice (7.5 6 1.5 pups per
litter; Student t-test, P , 0.001). Furthermore, this subfertility
FIG. 1. Deletion of Arid1a in the uterine stroma of Arid1a cKO mice. Quantitative PCR showed that uteri from virgin 12-wk-old cKO mice showed
decreased expression of Arid1a compared with control mice (A). Comparison of immunohistochemical staining for ARID1A in virgin 12-wk-old control
(B, C) and cKO (D, E) mice. Statistical significance (*P , 0.05) was calculated by Student t-test. Relative expression of Arid1a to 18s; G, glandular
epithelium; L, lumen; M, myometrium; S, uterine stroma. Bars ¼ 200 lm (B, D) and 50 lm.
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worsened over time. Although the total number of pups per
generation was lower for Arid1a cKO mice than for control
mice across all generations (two-way ANOVA, P ¼ 0.0064),
there was a progressive decline after the second pregnancy
(Fig. 2B). In addition, three out of nine Arid1a cKO mice were
infertile by 5 mo of age, whereas all control mice were still
fertile at this age, thus demonstrating the importance of Arid1a
in pregnancy.
Arid1a cKO Mice Had Low Penetrance of Uterine Tumors
after Pregnancy
After the fertility experiments, parous female mice were
dissected at 8 mo of age to evaluate the reproductive tract.
Control mice had grossly normal reproductive tracts, with no
uterine or ovarian tumors (Supplemental Fig. S4A and data not
shown). Parous control mice also had normal uterine histology,
with similar ARID1A expression as virgin female mice
(Supplemental Fig. S4B). Parous Arid1a cKO mice had normal
uterine histology, with similar ARID1A expression as virgin
female mice (Supplemental Fig. S4D). However, of the nine
parous Arid1a cKO mice, one mouse had a uterine tumor,
although both ovaries, both oviducts, and the opposite uterine
horn in this mouse were grossly and histologically normal
(Supplemental Fig. S4, A and D, and data not shown).
Histological analysis showed that the tumor was a benign
smooth muscle tumor with complete ablation of ARID1A in
both the uterine stroma and epithelium (Supplemental Fig.
S4C). In the normal horn, ARID1A expression was detected in
the nuclei of glandular and luminal epithelial cells (Supple-
mental Fig. S4D), similar to its expression in virgin Arid1a
cKO uteri. Overall, other than one benign uterine tumor, parous
Arid1a cKO and virgin Arid1a cKO female mice had normal
histology of female reproductive tract with no difference in
ARID1A expression or localization.
Virgin Arid1a cKO Mice Had Normal Reproductive Tracts,
Gonadotropin Levels, and Steroid Hormone Responses
Amhr2-Cre deletes the target allele in mesenchymal cells of
the uterus, oviduct, and ovary, all of which may contribute to
the subfertility phenotype observed in Arid1a cKO mice.
Previous in vivo models of subfertility with Amhr2-Cre have
shown defects in virgin or primigravid reproductive tract such
as Stat3 [34], Kras [37], Pten [41], Wnt4 [55], and Nr2f2 [59].
Therefore, we undertook a systematic approach to examine the
contribution of Arid1a deletion in each organ system in virgin
female mice.
To characterize the uterus of Arid1a cKO mice, virgin mice
were euthanized at 12 wk of age. Gross observation showed
that the uterus of Arid1a cKO mice was smaller than that of
control mice (Fig. 3A), and measurement of uterine weight
revealed significantly lighter uteri in Arid1a cKO mice than in
control mice (n ¼ 8, Student t-test, P , 0.05; Fig. 3B).
Furthermore, Arid1a cKO mice had significantly more uterine
glands per mm2 of surface area encapsulated by the
myometrium than control mice (n ¼ 4, P , 0.05; Fig. 3C),
as well as a 2-fold increase in levels of Foxa2 (n . 4, P ,
0.05; Fig. 3D), a marker of glandular epithelium [79]. Previous
work shows a critical role of Tgfbr1 in uterine smooth muscle
development [80, 81], but we observed no differences between
genotypes in levels of Tgfbr1 (data not shown). Both cyclin D1
(CCND1) and B-cell CLL/lymphoma 2 (BCL2) are regulated
by ARID1A in human non-small cell lung cancer [82]. We
further investigated molecular changes by measuring levels of
the cell cycle pathway- and apoptosis-related genes (Ccnd1)
and (Bcl2) in virgin uteri. We found a 1.4-fold (n . 4, P ,
0.05) and 2.2-fold (n . 4, P , 0.05) increase in Ccnd1 and
Bcl2 levels in unstimulated virgin adult Arid1a cKO uteri,
respectively (Fig. 3, E and F). However, there was no
difference in caspase-3 or Ki-67 staining in unstimulated
virgin Arid1a cKO and control uteri (data not shown).
Histological analysis demonstrated that at 4, 12, and 52 wk
of age, the morphology and histology of virgin ovaries was
similar between control and Arid1a cKO mice (Supplemental
Fig. S5, A–F). When superovulation was induced in immature
mice (n ¼ 23 per genotype), virgin control and Arid1a cKO
mice showed similar histology and numbers of corpora lutea
(Supplemental Fig. S5, G–L). Furthermore, when we quanti-
fied serum AMH levels as a measure of ovarian reserve, we
found no significant difference between virgin control (15.64
6 2.321 ng/ml, n ¼ 9) and virgin Arid1a cKO (12.93 6
2.268 ng/ml, n ¼ 8; Student t-test, P ¼ 0.179) mice.
To examine gonadotropin hormone levels, we measured
FSH and LH serum hormone levels of unstimulated, randomly
cycling adult Arid1a cKO and control mice. We observed no
FIG. 2. Arid1a cKO mice exhibited progressive subfertility. The reproductive ability of mice was tracked over a 6-mo breeding period. Arid1a cKO mice
had fewer pups per litter than control mice (A). Conditional knockout mice showed a progressive decline in fertility as evidenced by a lower total number
of pups per generation (B). Statistical significance (*P , 0.05) was calculated by Student t-test (A) or two-way ANOVA (B).
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significant differences between virgin control and Arid1a cKO
mice in FSH levels (control: 5.758 6 0.625 ng/ml, n ¼ 12;
cKO: 7.270 6 1.789 ng/ml, n¼ 10; Student t-test, P¼ 0.402)
or LH levels (control: 0.406 6 0.133 ng/ml, n ¼ 12; cKO:
0.222 6 0.0633 ng/ml, n ¼ 10; Student t-test, P ¼ 0.253). To
evaluate steroid hormone production, we measured serum E2
levels in virgin adult unstimulated, randomly cycling mice.
There were no significant differences in E2 levels between
control (11.62 6 7.437 pg/ml, n¼ 11) and Arid1a cKO (5.200
6 1.078 pg/ml, n ¼ 10; P ¼ 0.419) mice.
In primigravid mice, at 4.5 dpc, P4 levels in Arid1a cKO
pregnant mice (7.641 6 2.296 ng/ml, n ¼ 12) did not differ
FIG. 3. Uteri from virgin Arid1a cKO mice were smaller. Uterine horns from 12-wk-old Arid1a cKO mice were shorter than those in control mice (A).
Reproductive tracts from 12-wk-old cKO mice weighed less than those in control mice (B). Uteri from cKO mice displayed an increased number of uterine
glands (C), consistent with increased levels of Foxa2 expression as revealed by qPCR (D). Uteri from 12-wk-old cKO mice showed up-regulation of Ccnd1
(E) and Bcl2 (F). Statistical significance (*P , 0.05) was calculated by Student t-test. Relative Gene expression was relative to Rpl13a.
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from those in control pregnant mice (14.57 6 4.571 ng/ml, n¼
11; P¼ 0.426), indicating normal luteal function. When Arid1a
was deleted from the uterine epithelium using Pgr-Cre, there
was a significant loss of Pgr expression as well as loss of
expression of P4 responsive genes [21]. Therefore, we more
closely examined steroid hormone receptor and steroid
hormone response at the molecular level. Levels of Pgr (n .
4, P¼ 0.194) and estrogen receptor 1 (Esr1) (n . 4; Student t-
test, P¼ 0.817) were similar between unstimulated virgin adult
control and Arid1a cKO mice (Supplemental Fig. S6, A and
B). To determine whether the uteri of Arid1a cKO mice show
an altered response to steroid hormones, virgin unstimulated
mice were ovariectomized and treated with E2 for 3 days or P4
for 6 h [67, 83]. The uteri from virgin Arid1a cKO females
underwent a 5.2-fold increase in gross weight in response to
E2, similar to the 5.8-fold increase observed for virgin control
uteri (n¼ 6, Student t-test, P¼ 0.3468; Supplemental Fig. S6,
C and D). Both control and Arid1a cKO uteri showed a
significant increase in the estrogen responsive genes mucin 1
(Muc1), lactotransferrin (Ltf), and leukemia inhibitory factor
(Lif) levels after E2 treatment (Supplemental Fig. S6, E–G).
Furthermore, both virgin control and Arid1a cKO uteri showed
a significant increase in expression of epithelial and stromal P4
responsive genes, Indian hedgehog (Ihh), cytochrome P450,
family 26, subfamily A, polypeptide 1 (Cyp26a1), interleukin
13 receptor, alpha 2 (Il13ra2), heart and neural crest
derivatives expressed transcript 2 (Hand2), and homeobox
A10 (Hoxa10) levels in response to P4 (Supplemental Fig. S6,
H–L). These results indicate that virgin Arid1a cKO uteri
respond appropriately to E2 and P4.
Arid1a cKO Uteri Showed a Normal Decidualization
Response
To further investigate the subfertility phenotype, ovariecto-
mized virgin control and Arid1a cKO mice were treated with
hormones, and their uterus was mechanically stimulated to
induce decidualization. Gross and histological morphology of
the decidual and control horn were similar between virgin
control and Arid1a cKO uteri (Supplemental Fig. S7, A–D). In
addition, the ratio of decidualized to control horn weight was
equivalent in control and Arid1a cKO uteri (n ¼ 7; Student t-
test, P ¼ 0.1748; Supplemental Fig. S7E).
Primary cultures of human endometrial stromal fibroblasts
(hESCs) have the ability to undergo in vitro decidualization,
and this culture system has been used to demonstrate the
importance of several factors in uterine decidualization, such as
LIF [84], transient receptor potential cation channel, subfamily
C, member 1 (TRPC1) [85], transcription factor 23 (TCF23)
[86], uterine activing like kinase 2 (ALK2) [78], bone
morphogenetic protein 2 (BMP2) [87], and WNT4 [88].
Previous work has shown that ARID1A is deficient in hESCs
from women with endometriosis [21] and that in vitro
decidualization of hESCs from women with endometriosis
have a blunted in vitro decidualization response [89]. To
investigate the role of ARID1A in decidualization, we
performed small interfering RNA knockdown of ARID1A in
hESCs from women without endometriosis and then exposed
cells to conditions for in vitro decidualization. HESCs
transfected with siARID1A showed a 4.7-fold decrease in
ARID1A compared with hESCs transfected with siNT (n ¼ 7,
Student t-test, P , 0.001; Supplemental Fig. S8A); hESCs
transfected with siARID1A and then exposed to in vitro
decidualization conditions showed changes in morphology
similar to hESCs treated with siNT (data not shown). In
addition, hESCs treated with siNT or siARID1A (n ¼ 7)
showed similar increases in levels of decidualization markers
prolactin (PRL) (Student t-test, P ¼ 0.1441), a ligand of the
Wnt family (WNT4) (Student t-test, P ¼ 0.2146), and insulin-
like growth factor binding protein 1 (IGFBP1) (Student t-test,
P ¼ 0.2591; Supplemental Fig. S8, B–D). Therefore,
knockdown of ARID1A in primary cultures of hESCs did not
affect in vitro decidualization, similar to how deletion of
Arid1a in stromal cells of the mouse uterus in vivo did not
affect artificial decidualization (Supplemental Fig. S7).
Parous Arid1a cKO Mice Exhibited Reduced Fetal Viability
Our fertility studies showed a progressive decline in the
number of pups per litter, although female mice maintained
normal decidualization. To investigate the time during
pregnancy at which this phenotype becomes apparent, we
performed timed pregnancy studies by breeding female control
and Arid1a cKO mice at 6 wk with wild-type male mice.
During the first pregnancy, for control mice, the number of
implantation sites/female was similar to the number of viable
embryos/female on Embryonic Days 8.5 and 9.5, with no
resorbed embryos (Table 1 and Fig. 4A). By Embryonic Day
16.5, control mice had 10.3% resorbed embryos (Table 1).
During the first pregnancy for Arid1a cKO mice, fewer
implantation sites were observed on Embryonic Days 8.5 and
9.5 (Table 1 and Fig. 4B) compared to control. Additionally,
Arid1a cKO females had 17.4% resorbed embryos on
Embryonic Day 16.5 (Table 1). However, these differences
between genotypes were not statistically significant (Table 1).
Given the increase in resorbed embryos at Day 8.5, we
examined the histology of implantation sites at this time point
in the first pregnancy. We found hemorrhage and disruption in
the implantation sites of primigravid Arid1a cKO uteri on
Embryonic Day 8.5 (Fig. 4, C and D). Examination of the
antimesometrial myometrium showed a significant thickening
in primigravid Arid1a cKO mice compared with control mice
TABLE 1. Number of implantation sites and resorbed embryos.
Pregnancy
number Genotype
Embryonic
day
Implantation sites/female
(mean 6 SD)
Viable embryos/female
(mean 6 SD)
% Resorbed
embryos/female P-value
1 Control 8.5 (n ¼ 8) 9.1 6 0.5 9.1 6 0.5 0% 0.9106
9.5 (n ¼ 11) 9.3 6 0.4 9.3 6 0.4 0% 0.7749
16.5 (n ¼ 11) 8.1 6 0.3 7.2 6 0.4 10.3% 0.7401
1 cKO 8.5 (n ¼ 13) 8.4 6 0.3 8.2 6 0.3 2.3%
9.5 (n ¼ 8) 8.4 6 0.7 7.9 6 0.8 8.3%
16.5 (n ¼ 10) 7.9 6 0.4 6.5 6 0.5 17.4%
3 Control 16.5 (n ¼ 9)* 11.2 6 0.6 10.8 6 0.6 4.1% 0.0177*
cKO 16.5 (n ¼ 8)* 10.4 6 0.5 8.3 6 0.4 19.4%
* Statistical comparisons are between genotypes at similar embryonic day.
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(Fig. 4E). Although the thickness of the implantation sites was
less in primigravid Arid1a cKO mice than in control mice (Fig.
4E), there was no difference in the weight of viable
implantation sites (data not shown).
Given the subfertility that began after the second pregnancy,
we examined implantation sites in the third pregnancy. We
discovered a statistically significant increase in the number of
resorbed embryos in multigravida Arid1a cKO mice (19.4%)
compared to multigravida control mice (4.1%, chi-square; P¼
0.0177, Table 1 and Fig. 4, F and G). We performed
histological examination of placentas from Arid1a cKO and
control mice. On Embryonic Day 16.5 of the third pregnancy,
placentas from Arid1a cKO mice exhibited thinner junctional
and decidual zones than control mice (Fig. 4, H–J).
Molecular Differences Existed Between Parous and Virgin
Arid1a cKO Mice
To understand what factors contribute to the significant
subfertility phenotype beginning with the third litter in Arid1a
cKO mice, we studied multiparous females and their placentas.
During the third pregnancy, P4 levels in multiparous Arid1a
cKO pregnant mice at Embryonic Day 16.5 (23.34 6 5.030 ng/
ml, n ¼ 7) did not differ from those in control pregnant mice
(24.14 6 5.886 ng/ml, n ¼ 6; Student t-test, P ¼ 0.9195),
indicating normal luteal function in parous Arid1a cKO mice
during pregnancy. Gross morphology and histology of parous
ovaries was similar to virgin ovaries for both control and
Arid1a cKO mice showing normal corpora lutea and follicular
development (data not shown) further supporting normal luteal
function in the first pregnancy and subsequent pregnancies.
Finally, AMH levels were similar between virgin and
multiparous Arid1a cKO mice (data not shown).
Recently, two different transforming growth factor beta-
receptors, uterine activin like kinase 4 (ALK4) and uterine
activin like kinase 5 (ALK5), were shown to significantly
affect placental function when deleted in the uterus, leading to
subfertility and sterility [90, 91]. Given the changes in
placental morphology in parous Arid1a cKO females, we
examined uterine differences at the molecular level for the
underpinnings of this progressive subfertility phenotype. In
uteri from 6-mo fertility studies, examination of ARID1A
expression in the multiparous uterus showed a slight decrease
in ARID1A expression. Expression of ARID1A was present in
50%–80% of epithelial cells in the uteri of Arid1a cKO female
mice while expression of ARID1A was present in 80%–95% of
epithelial cells in the uteri of control female mice (Fig. 5, A and
B). Higher power magnification examination confirmed
nuclear ARID1A staining in both Arid1a cKO uteri and
control uteri with decreased expression in Arid1a cKO uteri
(Supplemental Fig. S9). Previous work had shown that deletion
of Arid1a with Pgr-Cre led to proliferation of uterine epithelial
cells during early pregnancy, but not uterine stromal cells [21].
In parous uterus, we found that Arid1a cKO uterine epithelial
and stromal cells showed increased proliferation compared to
multiparous control (Fig. 5, C and D). However, there was no
difference in PGR or ESR1 expression (Fig. 5, E–H). These
data suggest that ARID1A plays a role in both epithelial and
stromal cell proliferation in the uterus. Given the subtle
changes in thickness of antimesometrium at Embryonic Day
8.5 in the first pregnancy and the more significant changes in
placental morphology at Embryonic Day 16.5 in the third
pregnancy, we focused our molecular studies on the placenta.
We discovered a 33% decrease in Arid1a expression in the
placentas from Arid1a cKO mothers during the third pregnancy
(Fig. 6A), likely an indirect effect and not an effect of knockout
on the placenta. Similarly, there was a significant decrease in
SWI/SNF related, matrix associated, actin dependent regulator
of chromatin, subfamily A, member 4 (Smarca4), an ARID1A
binding partner, expression (Fig. 6B). To gain insight into the
molecular underpinnings of the placental phenotype, we
examined the levels of molecules involved in placental
structure and function. We discovered decreased expression
of nodal growth differentiation factor (Nodal), a transforming
growth factor beta-receptor ligand (Fig. 6C) in placentas from
Arid1a cKO female mice. Additionally, placentas from Arid1a
cKO mice exhibited decreased protocadherin 12 (Pcdh12), a
marker of glycogen trophoblast cells, and trophoblast specific
protein alpha (Tphpa), a marker of spongiotrophoblast cells
compared to placentas from control female mice (Fig. 6, D and
FIG. 4. Arid1a cKO mice showed increased embryo resorption during the third pregnancy. Gross morphology of primigravid control (A) and cKO (B)
uteri on Embryonic Day 8.5. Conditional knockout implantation sites (D) on Embryonic Day 8.5 showed evidence of hemorrhage, which was not
observed at control implantation sites (C). Conditional knockout antimesometrial decidua was thicker than those in control mice (E). Conditional knockout
mice (G) showed more resorbed embryos (arrows) than control mice (F) on Embryonic Day 16.5 of the third pregnancy. Midsagittal sections of placental
tissue obtained on Embryonic Day 16.5 from control (H) and cKO (I) mice of third pregnancy. Conditional knockout mice had a thinner junctional zone
and decidua compared with control mice (J). AMD, antimesometrial decidua; MD, mesometrial decidua; De, decidua; Jz, junctional zone; Lz,
labyrinthine zone; Statistical significance (*P , 0.05) was calculated by two-way ANOVA. Bars ¼ 500 lm (C, D, H, I).
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E). Compared with placentas from control female mice,
placentas from Arid1a cKO female mice showed significantly
lower levels of Ptgs2 (Fig. 6F), which is important for
ectoplacental cone formation [92]. Levels of molecules
involved in vasculogenesis (Vegfa) and angiogenesis (Angpt1)
were also significantly decreased in placentas from cKO
females (Fig. 6, G and H). Furthermore, levels of Corin, which
is critical for trophoblast invasion [93], were significantly
reduced in placentas from Arid1a cKO females (Fig. 6I). There
were no differences between genotypes in levels of Gcm1,
which is important for chorioallontoic branching [94], or
Vcam1, which is critical for vascular endothelium formation
[95] (Fig. 6, J and K).
DISCUSSION
Many previous studies have focused on the role of ARID1A
in cancer, particularly as a tumor suppressor or driver mutation
in tumors of the female reproductive tract [9, 11, 13, 15, 20,
23]. Thus, our original hypothesis was that deletion of Arid1a
with Amhr2-Cre would give rise to ovarian tumors in mice.
Here, by conditionally deleting Arid1a in mesenchymal-
derived cells of the female reproductive tract, we provide
evidence that loss of Arid1a is not sufficient for tumor
formation, suggesting that additional mutations are required for
tumor formation in the mouse female reproductive tract.
However, we show that ARID1A is important for normal
placental morphology and fertility in parous female mice.
Female mice with conditional deletion of Arid1a show a
progressive decline in fertility with higher parity, with a loss of
pups in the postimplantation phase beginning with the third
pregnancy.
Studies suggest that ARID1A plays a key role in the
proliferation of several types of cancers and is associated with
genetic aberrations in cyclin-dependent kinases [96]. For colon
cancer, non-small cell lung cancer, and gastric cancer,
knockdown of ARID1A enhances cellular proliferation in vitro,
and restoration of ARID1A expression suppresses cellular
proliferation [82, 97, 98]. Likewise, we found that loss of
Arid1a up-regulated Ccnd1 in the virgin uterus in vivo.
Additionally, we also observed up-regulation of the pro-
apoptotic gene Bcl2 in the Arid1a cKO uterus. Therefore, we
believe that the balance of proliferation and apoptosis may
preclude the development of cancer in virgin female Arid1a
cKO mice. Other studies using adenovirus-driven Cre to delete
Arid1a from the ovarian surface epithelium showed that Arid1a
depletion is not sufficient to induce ovarian tumors in mice
[22]. Additionally, our work deleting Arid1a in the uterus using
Pgr-Cre did not develop endometrial tumors [21]. Consistent-
ly, we found that Arid1a deletion from the ovarian surface
epithelium using Amhr2-Cre did not induce ovarian tumors in
virgin female mice. Thus, we speculate that female reproduc-
tive tract cancers in mice require additional genetic hits along
with loss of Arid1a to give rise to malignant tumors.
Interestingly, Arid1a cKO female mice had significant
subfertility that became apparent after the second pregnancy.
Translationally, this may be comparable to secondary infertility
although most of our Arid1a cKO mice were not completely
infertile. Male factors did not contribute because we were using
fertility-proven intact wild-type male mice for our experiments.
Given the deletion of Arid1a in the somatic cells of the ovary,
ovarian dysfunction was critically evaluated. In primigravid
and multigravida female Arid1a cKO mice, we found similar
P4 levels as control as well as similar numbers of corpora lutea.
AMH levels, a measure of ovarian reserve, were also similar
between Arid1a cKO and control for both virgin and parous
female mice. Gonadotropin levels were also similar between
virgin Arid1a cKO and control female mice. Thus, we do not
see an obvious luteal phase defect or other ovulatory
dysfunction in either virgin or parous Arid1a cKO female
mice. However, it remains possible that a more subtle luteal
defect may contribute to the reduced pups per litter.
Anatomically, Arid1a cKO had normal oviductal, uterine,
and cervical histology for both virgin and parous female mice,
and we found no gross or histological evidence of endome-
triosis. Thus, we do not believe that anatomical factors lead to
secondary subfertility. In women undergoing an evaluation for
secondary infertility, this would fall under the category of
unexplained infertility and is typically thought to be caused by
endometrial dysfunction. Only recently have genomewide
FIG. 5. After 6-mo fertility studies, parous uteri from Arid1a cKO mice showed increased proliferation. ARID1A expression was present in .95% of
epithelial cells from control (A) but only 50%–80% of epithelial cells from cKO (B) uteri. However, increased proliferation in both epithelium and stromal
compartments was apparent in cKO (D) compared to control (C) parous uteri by Ki67 staining. Expression of ESR1was similar between control (E) and cKO
(F) parous uteri. Similarly, expression of PGR was similar between control (G) and cKO parous uteri (H). GE, glandular epithelium; L, lumen; LE, luminal
epithelium; M, myometrium; S, uterine stroma. Bars ¼ 25 lm (A, B) and 50 lm (C–H).
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profiling techniques been used to identify these subtle
molecular changes [99–101].
Our virgin Arid1a cKO female mice had normal implanta-
tion, normal decidualization, and normal pregnancy outcomes
in the first pregnancy. However, examination of parous uteri
showed an increase in both epithelial and stromal proliferation
(Fig. 5) with deletion of ARID1A that was not present in virgin
uteri even at 1 yr of age (data not shown). Little has been
published about the molecular differences between virgin and
parous uteri. We can only speculate that the deletion of Arid1a
led to indirect changes in gene expression that affected uterine
remodeling after pregnancy. We speculate that subtle changes
in the uterine stroma after remodeling postpartum lead to
changes in placentation with subsequent pregnancies. Howev-
er, significant work needs to be done to understand the subtle
molecular changes between the parous and the virgin uterus
before we can tease out the specific changes associated with
loss of Arid1a.
Only after pregnancy, one female Arid1a cKO mouse was
found to have a benign uterine tumor that exhibited a lack of
ARID1A in epithelial cells. Given the low penetrance (one in
nine) of tumors in parous uteri, a significantly larger number of
FIG. 6. Placentas from Arid1a cKO mice showed molecular dysregulation. Placental mRNA levels of Arid1a (A), Smarca4 (B), Nodal (C), Pcdh12 (D),
Tpbpa (E), Ptgs2 (F), Vegfa (G), Angpt1 (H), and Corin (I) were decreased in cKO mice on Embryonic Day 16.5 of the third pregnancy. There was no
difference in levels of Gcm1 (J) or Vcam1 (K). Statistical significance (*P , 0.05) was calculated by Student t-test. Gene expression was measured relative
to Gapdh.
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female mice would need to be examined to determine the
statistical significance of this result. Previous studies suggest
that glandular and luminal epithelial cells of the uterus are
regenerated from uterine stromal cells after pregnancy in
Amhr2-Cre mice [102]. After one pregnancy, at most 50% of
epithelial cells were regenerated from stroma in a process of
mesenchymal epithelial transition (MET) [103]. Thus, deple-
tion of ARID1A in the epithelium could result from Arid1a
deletion in uterine stromal cells. This could account for the loss
of ARID1A in the one female mouse with a tumor after
pregnancy. Interestingly, recurrent copy number variants of
Arid1a have recently been discovered in uterine leiomyomata
tumors [104], which are the most translationally equivalent
human disease to the one tumor. However, other parous Arid1a
cKO female mice examined had expression of ARID1A in the
epithelium and no tumors. Deletion of Arid1a with Pgr-Cre
deleted Arid1a in the epithelium and did not result is similar
tumors. However, these female mice were completely sterile
and thus could not be studied in the multiparous state [21].
Indeed, we did see a decrease in ARID1A staining in the
epithelium after repetitive pregnancy (Fig. 5 and Supplemental
Fig. 9) in Arid1a cKO uteri, suggesting that MET is occurring
in this model. Similar to published work, we saw at most 50%
loss of ARID1A staining in epithelial cells after repetitive
pregnancy. While previous work had only examined MET after
1 pregnancy, we have shown that MET remains after repetitive
pregnancies and may be long lasting. The MET effect does not
seem to be exponential with each pregnancy (i.e., loss of 50%
with first pregnancy, loss of another 50% with second
pregnancy). However, we cannot speculate as to whether
repetitive pregnancy allows for regeneration of ARID1A-
positive epithelial cells from ARID1A-positive epithelial cells
based on our experimental time point. While a partial deletion
of ARID1A does occur in the epithelial cells of the uterus in
the Arid1a cKO mice, the phenotype is different than the
complete deletion of ARID1A in the epithelial cells of the
uterus of the Pgr-Cre female mice. However, it remains
possible that the epithelial cell phenotype in the Amhr2-Cre
female mice contributes to the reduced pups per litter.
Finally, multiparous Arid1a cKO female mice developed
significantly abnormal placentas. The placenta is critical for
proper fetal development. Translationally, placental abnormal-
ities can lead to significant maternal morbidities such as pre-
eclampsia and fetal complications such as fetal growth
restriction or fetal demise. While we did not find gross
differences in size of live born pups (data not shown), we did
discover significant resorption of embryos at Embryonic Day
16.5 in the third litter of Arid1a cKO female mice (Table 1and
Fig. 4). The placental morphology was abnormal (Fig. 4), and
molecular markers of abnormal placental morphology con-
firmed these differences (Fig. 6). ARID1A is a critical player in
chromatin remodeling, cellular proliferation, and gene regula-
tion [2, 104–108]. Although multiple studies have focused on
the role of epigenetic markers in chromatin remodeling in the
placenta, little is known about the actual gene products
involved in placental chromatin remodeling. One study shows
that in vitro depletion of SMARCA4 (also known as BRG1),
which is a critical member of the SWI/SNF chromatin-
remodeling complex and a known protein-binding partner for
ARID1A [109] that plays a key role in trophoblast stem cell
self-renewal [110], has a similar effect on cellular proliferation
as the depletion of ARID1A [111]. We found a decrease in
both Arid1a and Smarca4 expression in placentas from
multiparous Arid1a cKO females (Fig. 6). In the present study,
the molecular markers examined in placentas from Arid1a cKO
mice are at best suggestive of abnormal placental morphology.
Although they do not provide a complete understanding of the
molecular mechanism of the effect of Arid1a deletion, they
suggest that loss of Arid1a in the uterus impairs placental
function, evidenced by a subfertility phenotype, increased
resorbed embryos, and a thinner junctional zone at implanta-
tion sites.
In conclusion, we found that Arid1a deletion alone is
insufficient to induce tumorigenesis in the female reproductive
tract of mice. ARID1A regulates embryo implantation and
development of a functional placenta. Future studies of our
Arid1a cKO mouse model should provide molecular insight
into the delicate function of SWI/SNF-mediated chromatin
remodeling in placental function.
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